MedPath

Tong-Xie-Yao-Fang Granules for Diarrhea-predominant Irritable Bowel Syndrome

Phase 2
Completed
Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Interventions
Drug: Placebo
Drug: Tong-Xie-Yao-Fang
Registration Number
NCT02538692
Lead Sponsor
Chengdu University of Traditional Chinese Medicine
Brief Summary

The purpose of this study is to test the efficacy and safety of a traditional Chinese medication Tong-Xie-Yao-Fang for patients with diarrhea-predominant irritable bowel Syndrome (IBS-D).

Detailed Description

Participants: The sample size of this trial is 118, to test an odds ratio of 3.5 at a significance of 0.05 and power of 0.8.

Intervention: Tong-Xie-Yao-Fang versus placebo Data collection: Standard operation procedure will be developed for how to interviewing the participants, how to use the IBS diary, how to enter the data into the electronic case report forms.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
160
Inclusion Criteria
  • Being diagnosed as IBS according to the Rome III criteria;
  • Diarrhea was present for at least 75% of the time;
  • With a TCM differentiation as "liver stagnation and spleen defficiency"
  • Had a colonoscopy within a year to rule out other bowel diseases.
Exclusion Criteria
  • Organic gastrointestinal disease, such as colorectal cancer, inflammatory bowel disease, advanced colonic polyp;
  • Had gastrointestinal surgery within a year;
  • Used durgs that affect gastrointestinal motility;
  • Had psychological disorder;
  • Serious disease in other system, which may bias the outcome measures.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboIt is a placebo that made with similar appearance and taste as the Tong-Xie-Yao-Fang granules.
Tong-Xie-Yao-FangTong-Xie-Yao-FangTong-Xie-Yao-Fang is a classic formula of traditional Chinese medicine for IBS-D. It is composed of 4 herbs: Radix Paeoniae Alba, Ledebouriella seseloides Wolff, pericarpium citri reticulatae and Rhizoma Atractylodis Macrocephalae. The granules will be administrated for thrice daily at a dose of 15g per time. The total duration of treatment is 4 weeks.
Primary Outcome Measures
NameTimeMethod
the proportion of patients who had adequate relief of global IBS-D symptoms for at least 2 of the 4 weeks.4 weeks after initiation of treatment
Secondary Outcome Measures
NameTimeMethod
An visual scale rating the degree of IBS-D symptomsbaseline(week 0), week 4, week 8, week 12

The scale ranges from 0 to 10. The score 0 indicates the mildest degree, while the 10 indicates the most serious degree.

Stool frequency per weekbaseline(week 0), week 4, week 8, week 12
Proportion of adverse eventsweek 4

Trial Locations

Locations (1)

Teaching Hospital of Chengdu University of TCM

🇨🇳

Chengdu, Sichuan, China

© Copyright 2025. All Rights Reserved by MedPath